EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma

Rupesh Kotecha iD, Mei-Yin Polley iD, Michael A Vogelbaum iD, Arie Perry iD, Lynn Ashby, Jignesh M Modi, Anthony M Alleman, Christina I Tsien, Igor Johan Barani iD, Jing Li, Steve Braunstein iD, Anthony C Whitton und 14 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-01441 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Rupesh Kotecha und 25 weiteren Autor:innen. Beteiligte Einrichtung: Miami Cancer Institute, Miami, FL. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NRG Oncology RTOG 0539 was a prospective phase II trial of risk-adapted radiotherapy for patients with WHO grade 1-3 meningioma. Low-risk (group 1, n = 60) was defined as a grade 1 tumor after gross total resection or subtotal resection (GTR/STR) and prospectively monitored. Intermediate-risk (group 2, n = 52) was defined as recurrent grade 1 or newly diagnosed grade 2 tumor after GTR and treated with radiotherapy (54 Gy). High-risk (group 3, n = 53) included a newly diagnosed grade 2 tumor after STR, newly diagnosed grade 3 tumor, or recurrent grade 2 or 3 tumor and treated with radiotherapy (60 Gy). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The median follow-up times for the low-, intermediate-, and high-risk cohorts were 12.1, 12.0, and 11.1 years, respectively. The 10-year PFS and OS rates for the low-, intermediate-, and high-risk cohorts were 85.2% and 94.1%, 72.2% and 84.7%, and 42.5% and 51.1%, respectively. Five patients (9.6%) and eight patients (15.1%) had a grade 3+ toxicity attributed to radiotherapy in the intermediate- and high-risk cohorts, respectively. The long-term outcomes using this risk-adapted approach support observation for low-risk patients, inform radiotherapy patient selection and practice standards for intermediate- and high-risk patients, and provide comparative benchmarks for future trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsHumansFemaleMiddle AgedMaleAdultAgedProspective StudiesProgression-Free SurvivalNeoplasm Recurrence, LocalNeoplasm Grading

Autor:innen und Institutionen

  • Miami Cancer Institute, Miami, FL.
  • NRG Oncology Statistics and Data Management Center, Chicago, IL.
  • University of Chicago, Chicago, IL.
  • Moffitt Cancer Center, Tampa, FL.
  • University of California San Francisco, San Francisco, CA.
  • Saint Joseph's Hospital and Medical Center, Phoenix, AZ.

ORCID-Profile: Rupesh Kotecha, Mei-Yin Polley, Michael A Vogelbaum, Arie Perry, Igor Johan Barani, Steve Braunstein, Joseph A Bovi, Scott M Lindhorst, Dennis C Shrieve, Clifford G Robinson, Hui-Kuo G Shu, Prashant Vempati, Mark Vikas Mishra, John H Suh, Grant K Hunter, Minesh P Mehta

Förderung

  • NCI NIH HHS

Zitieren

APA

Kotecha, R., Polley, M. Y., Vogelbaum, M. A., Perry, A., Ashby, L., Modi, J. M., Alleman, A. M., Tsien, C. I., Barani, I. J., Li, J., Braunstein, S., Whitton, A. C., Bovi, J. A., Deb, N., Lindhorst, S. M., Shrieve, D. C., Robinson, C. G., Shu, H. G., Vempati, P., …, & Rogers, C. L. (2026). Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01441

Vancouver

Kotecha R, Polley MY, Vogelbaum MA, Perry A, Ashby L, Modi JM, et al. Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-01441

BibTeX
@article{Kotecha2026,
  author = {Kotecha, Rupesh and Polley, Mei-Yin and Vogelbaum, Michael A and Perry, Arie and Ashby, Lynn and Modi, Jignesh M and Alleman, Anthony M and Tsien, Christina I and Barani, Igor Johan and Li, Jing and Braunstein, Steve and Whitton, Anthony C and Bovi, Joseph A and Deb, Nimisha and Lindhorst, Scott M and Shrieve, Dennis C and Robinson, Clifford G and Shu, Hui-Kuo G and Vempati, Prashant and Mishra, Mark Vikas and Suh, John H and Bloom, Beatrice and Hunter, Grant K and Won, Minhee and Mehta, Minesh P and Rogers, C Leland},
  title = {Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-01441}
}
Kostenlos starten →